oral IDO1 inhibitor

clinical candidate in Ph. I/II combo for cancer

reversed amide of linrodostat

ACS Med. Chem. Lett., Jan. 28, 2021

Bristol Myers Squibb, Lawrence Township, NJ

Chemical structure of molecule BMS-986242

The BMS IDO1 inhibitor, BMS-986242, is a clinical candidate in a Ph. I/II study in combination with nivolumab for cancer. Like me, you probably had to look twice at…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: